# Xinhe Bio (新合生物)
Xinhe Bio (新合生物, formally Shenzhen Xinhe Biomedical Technology Co., Ltd.) is a Chinese biotechnology company founded in 2017 and based in Shenzhen that develops RNA platform-based therapeutics, combining artificial intelligence with multi-omics data to predict tumor neoantigens and design RNA drug candidates, with its lead program a gastric-cancer mRNA neoantigen vaccine that entered China's regulatory review in 2023.[1](https://www.vcbeathealth.com/article/43527) • [2](https://www.vcbeathealth.com/article/37270)
| Key facts | |
| --- | --- |
| Founded | 2017, Shenzhen[1](https://www.vcbeathealth.com/article/43527) |
| Founder | Dr. Wang Yi[1](https://www.vcbeathealth.com/article/43527) |
| Sector | Biotech: RNA therapeutics, mRNA oncology vaccines[1](https://www.vcbeathealth.com/article/43527) |
| Funding | RMB 250 million Series A (Dec 2020); CNY 500 million round reported Dec 2021 (directory-sourced)[1](https://www.vcbeathealth.com/article/43527) • [3](https://ecosystem.startupestonia.ee/companies/xinhe_biotechnology) |
| Investors | Kunlun Capital, IDG Capital, Yahui Capital (2020); CDH, PICC Capital, Zhou Yahui, Shunxi, Jiayin listed for 2021 (unverified)[1](https://www.vcbeathealth.com/article/43527) • [3](https://ecosystem.startupestonia.ee/companies/xinhe_biotechnology) |
| Lead program | XH101, an mRNA tumor neoantigen vaccine for gastric cancer; IND accepted by CDE on March 4, 2023[2](https://www.vcbeathealth.com/article/37270) |
| Status | Last independently reported event: March 2023 IND acceptance; 2026 operations not independently confirmed |
## What Xinhe Bio does
The company is one of a small group of Chinese enterprises working on RNA platform-based therapeutics. Its approach combines a multi-omics big data collection platform and biological database with AI and bioinformatics tools for drug target mining and automated drug design.[1](https://www.vcbeathealth.com/article/43527) The central technical problem is neoantigen prediction: identifying mutant peptide fragments on a patient's tumor that the immune system can be trained to attack. Company-reported benchmarks state that its proprietary ALPINE tumor neoantigen prediction platform achieves over 30% higher prediction accuracy than other public algorithms, and that its MATHLA model outperforms the widely used academic tools netMHCpan 4.0 and MHCflurry; these comparisons come from the company and have not been independently verified.[1](https://www.vcbeathealth.com/article/43527)
Its pipeline spans tumor immunotherapy, vaccines, rare diseases, and metabolic disorders. The most advanced area is public (shared) neoantigen programs for gastric, esophageal, lung, and liver cancer.[1](https://www.vcbeathealth.com/article/43527)
## Founders and team
The company is led by founder Dr. [Wang Yi](https://www.edgepedia.org/wang-yi). Its core research team comprises more than 50 members, including PhDs and postdoctoral researchers from Harvard, Cornell, Carnegie Mellon, Peking University, Tsinghua, and the [Chinese Academy of Sciences](https://www.edgepedia.org/chinese-academy-of-sciences).[1](https://www.vcbeathealth.com/article/43527) Further biographical detail about the founder was not available in the sources retrieved for this article.
## Funding history
**Series A, December 2020.** Xinhe Bio completed a RMB 250 million [Series A round](https://www.edgepedia.org/series-a-round) led by Kunlun Capital, with participation from IDG Capital and existing investor Yahui Capital.[1](https://www.vcbeathealth.com/article/43527) The company designated the proceeds for GMP facility construction, accumulation of real-world neoantigen data, expansion of clinical protocols, and investigational new drug (IND) applications for multiple RNA drug candidates.[1](https://www.vcbeathealth.com/article/43527)
**A+ round, December 2021.** A CNY 500 million round in December 2021 is listed by a directory profile with [CDH Investments](https://www.edgepedia.org/cdh-investments), PICC Capital, Zhou Yahui, Shunxi Private Equity Fund Management, and Jiayin Fund as investors.[3](https://ecosystem.startupestonia.ee/companies/xinhe_biotechnology) This figure rests on the directory listing alone and is unverified by independent reporting in the retrieved results; no source confirms who led the round. Taking the two reported rounds together, the company raised roughly RMB 750 million across the two rounds through December 2021.[1](https://www.vcbeathealth.com/article/43527) • [3](https://ecosystem.startupestonia.ee/companies/xinhe_biotechnology)
## Technology and pipeline
By 2021 the company had built a three-site footprint: an RNA drug R&D center in Beijing, an AI bioinformatics research laboratory in Shenzhen, and a GMP production facility in [Guangzhou](https://www.edgepedia.org/guangzhou), plus partnerships with dozens of hospitals across China for data collection and clinical work.[1](https://www.vcbeathealth.com/article/43527) For its gastric-cancer shared neoantigen program, the company reported completing antigen screening, immunogenicity testing, and retrospective clinical validation, and it was running exploratory neoantigen vaccine trials in intermediate to advanced-stage tumor patients.[1](https://www.vcbeathealth.com/article/43527)
The concrete regulatory milestone came on March 4, 2023, when the Center for Drug Evaluation (CDE) of the [National Medical Products Administration](https://www.edgepedia.org/national-medical-products-administration) accepted the IND application for XH101 Injection under acceptance number CXSL2300170. According to trade reporting, XH101 is a first-in-class therapeutic mRNA tumor vaccine targeting gastric cancer public neoantigens, screened and validated with the company's neoantigen prediction, Elispot immunogenicity, and cell cytotoxicity platforms. Company-reported preclinical data indicate the vaccine can elicit T-cell immune responses and induce tumor cell killing.[2](https://www.vcbeathealth.com/article/37270)
## References
1. [Xinhe Biologics Secures RMB 250 Million Series A Financing Led by Kunlun Capital to Advance RNA Therapeutics Pipeline (VCBeat)](https://www.vcbeathealth.com/article/43527)
2. [Xinhe Bio's First-in-Class mRNA Tumor Neoantigen Vaccine XH101 Receives IND Approval in China (VCBeat)](https://www.vcbeathealth.com/article/37270)
3. [Xinhe Biotechnology — funding table (directory profile)](https://ecosystem.startupestonia.ee/companies/xinhe_biotechnology)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Cell and gene therapy developers › RNA and oligonucleotide therapeutics*
*Initially written Sep 17, 2026 · Reviewed: Sep 18, 2026 · Edited: Sep 18, 2026; Oct 11, 2026 · Last review: Sep 18, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license